High flow or titrated oxygen for obese medical inpatients: a randomised crossover trial. Issue 10 (20th November 2017)

• Record Type: Journal Article
• Authors: Pilcher, Janine; Richards, Michael; Eastlake, Leonie; McKinstry, Steven J; Bardsley, George; Jefferies, Sarah; Braithwaite, Irene; Weatherall, Mark; Beasley, Richard
• Is Part Of: Medical journal of Australia. Volume 207:Issue 10(2017)
• Page Start: 430
• Page End: 434
• Publication Date: 2017-11-20
• Subjects: Respiratory tract diseases; Medicine -- Periodicals; Medicine; Médecine -- Périodiques; Medicine; Periodical; Periodicals; Electronic journals; 610
• DOI: 10.5694/mja17.00270
• Languages: English
• ISSNs: 0025-729X

Abstract

Abstract: Objective: To compare the effects on transcutaneous carbon dioxide tension (Ptco2 ) of high concentration and titrated oxygen therapy in medical inpatients with morbid obesity who were not selected for a pre‐existing diagnosis of obesity hypoventilation syndrome. Design: A randomised, crossover trial undertaken between February and September 2015. Setting: Internal medicine service, Wellington Regional Hospital, New Zealand. Participants: 22 adult inpatients, aged 16 years or more, with a body mass index exceeding 40 kg/m 2 . Interventions: Participants received in random order two 60‐minute interventions, with a minimum 30‐minute washout period between treatments: titrated oxygen therapy (oxygen delivered, if required, via nasal prongs to achieve peripheral oxygen saturation [Spo2 ] of 88–92%), and high concentration oxygen therapy (delivered via Hudson mask at 8 L/min, without regard to Spo2 ). Ptco2 and Spo2 were recorded at 10‐minute intervals. Main outcome measure: Ptco2 at 60 minutes, adjusted for baseline. Results: Baseline Ptco2 was 45 mmHg or lower for 16 participants with full data (73%). The mean difference in Ptco2 between high concentration and titrated oxygen therapy at 60 minutes was 3.2 mmHg (95% CI, 1.3–5.2 mmHg; P = 0.002). Conclusion: High concentration oxygen therapy increases Ptco2 in morbidly obese patients. Our findings support guidelines that advocate oxygen therapy, if required in patients with morbid obesity, be titrated to achieve a target Spo2 of 88–92%. Clinical trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12610000522011.